Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
about
Genome-wide association meta-analysis for total serum bilirubin levelsEffect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancerInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsInvestigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Impact of OATP transporters on pharmacokinetics.Genetic influences on serum bilirubin in American Indians: The Strong Heart Family StudyThe role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Interactions of green tea catechins with organic anion-transporting polypeptides.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerEltrombopag increases plasma rosuvastatin exposure in healthy volunteers.A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicityPharmacogenetic pathway analysis of docetaxel elimination.The Chinese Herb Jianpijiedu Contributes to the Regulation of OATP1B2 and ABCC2 in a Rat Model of Orthotopic Transplantation Liver Cancer Pretreated with Food Restriction and Diarrhea.OATP1B1 polymorphism as a determinant of erythromycin disposition.Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobioticsCombined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Role of OATP transporters in the disposition of drugs.Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.Formed and preformed metabolites: facts and comparisons.Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibitionLow systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytes.Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines.Cyanobacterial toxins and liver disease.Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP).Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Role of transporters in drug interactions.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Effect of OATP-binding on the prediction of biliary excretion.Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.New QSAR Models for Human Cytochromes P450, 1A2, 2D6 and 3A4 Implicated in the Metabolism of Drugs. Relevance of Dataset on Model Development.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
P2860
Q24658179-C5C655E3-8C6D-4CE3-B58F-A424978DE927Q24658301-3C7A37A1-5B2B-42B2-86B7-283E8B12C059Q28239708-5D6EE81A-B3AA-40E1-AE85-E341B0C6A074Q34570893-23FFD02F-FC0F-4DA7-A945-2305C7A1316EQ34612244-627CE9D9-F081-4B72-A789-519205CE0C9AQ34614162-92D2656C-8130-4061-8422-24E347F173F3Q34631971-61D9486C-2751-4FAF-BE8A-252475B887A1Q34856952-E25EBAE7-42B2-4437-B1D4-C1879F8FCF38Q35112055-FF428226-9B48-465B-B9F5-7F9E019B578FQ35183649-70537AAF-1C21-4C1D-A94A-398091B17EB0Q36061736-B8E51EBE-565F-406A-9CF2-882DCC757235Q36182023-F85FD42C-ECA7-47C2-8C49-F1D61815CF73Q36333098-69105421-7CA5-45A3-8FBC-F3F2082CD602Q36339094-B4CDA506-57A8-4C83-A897-304149FBFA46Q36634986-391D9B1F-215B-40C3-A0A7-80829871B235Q36709153-D4F52BC6-8D9B-4612-9765-7C12FC79D035Q37074085-8F1414C9-FEE7-4E8E-8BFD-99734DADB984Q37093336-EE77BD64-64E3-48D9-82D5-6A2AEEFCD836Q37277366-13D3D560-8812-4316-B505-8DCD39AEE55DQ37279800-C31EAFF9-2824-4924-9FAD-E23252AF390CQ37304966-590C5419-181F-485F-9456-8890D63147B5Q37444375-BBB897D3-16E8-4FA0-B08A-415E1968D104Q37481450-1E6F6CC7-2BD4-4E69-A62C-AE5D5F4411C2Q37583348-55DF07E2-6E5E-486B-BD2B-16721F04AD4CQ37604385-7F62DB08-624A-4A4A-9385-7A0E600613BEQ37669193-0BF1EA76-FC49-4923-AE85-2F8369850759Q37833013-38FE9961-EC86-4881-80E5-2C3010152041Q37855801-59FB8278-83CF-4D6B-96F2-4085119EB8F3Q37955160-14D25344-25D2-4F49-BF93-4DB8C5E71BAEQ37964577-661CBD48-1B9D-42DA-86B6-38A18225D171Q38003174-E1CEE590-7629-4757-88A3-D8BBCBDE4E26Q38436729-D1D4346C-D1E2-4B7D-B790-9022017F8E19Q38439120-FDD03BE5-122F-4805-B794-E7E7EB44E02BQ38817753-CFDE732A-4082-471B-B4CB-B1447588202FQ39349116-C1D0D90A-E772-4414-A0C0-1AC6CA18CEBEQ39535158-E6ACBF01-75C0-4BD0-870D-2C9BFDA8CD87Q40488073-C4E506C0-A061-4C71-974B-8F39498140D8Q46088850-0D27B8B9-3DD3-43E0-90BA-D4C7CE99B0CBQ47584564-8F952DCF-E5D6-4164-A70D-F797DD8FB2A0Q48202863-BC93A7E5-8E37-42BD-A55E-C6DC450C4974
P2860
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Role of the liver-specific tra ...... in governing drug elimination.
@ast
Role of the liver-specific tra ...... in governing drug elimination.
@en
type
label
Role of the liver-specific tra ...... in governing drug elimination.
@ast
Role of the liver-specific tra ...... in governing drug elimination.
@en
prefLabel
Role of the liver-specific tra ...... in governing drug elimination.
@ast
Role of the liver-specific tra ...... in governing drug elimination.
@en
P2860
P356
P1476
Role of the liver-specific tra ...... in governing drug elimination.
@en
P2093
Nicola F Smith
William D Figg
P2860
P304
P356
10.1517/17425255.1.3.429
P407
P577
2005-10-01T00:00:00Z